146 related articles for article (PubMed ID: 36129942)
21. The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.
Morra F; Merolla F; Napolitano V; Ilardi G; Miro C; Paladino S; Staibano S; Cerrato A; Celetti A
Oncotarget; 2017 May; 8(19):31815-31829. PubMed ID: 28415632
[TBL] [Abstract][Full Text] [Related]
22. A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.
Palit SAL; van Dorp J; Vis D; Lieftink C; Linder S; Beijersbergen R; Bergman AM; Zwart W; van der Heijden MS
Sci Rep; 2021 Jul; 11(1):13683. PubMed ID: 34211036
[TBL] [Abstract][Full Text] [Related]
23. CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression.
Chen H; Dong K; Ding J; Xia J; Qu F; Lan F; Liao H; Qian Y; Huang J; Xu Z; Gu Z; Shi B; Yu M; Cui X; Yu Y
Cancer Lett; 2024 Apr; 587():216725. PubMed ID: 38364963
[TBL] [Abstract][Full Text] [Related]
24. Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing?
De Giorgi U; Giunta EF; Verzoni E; Procopio G
Ann Oncol; 2023 Sep; 34(9):729-731. PubMed ID: 37406813
[No Abstract] [Full Text] [Related]
25. Blocking lipid synthesis induces DNA damage in prostate cancer and increases cell death caused by PARP inhibition.
Ribeiro CF; Rodrigues S; Bastos DC; Fanelli GN; Pakula H; Foiani M; Zadra G; Loda M
Sci Signal; 2024 Apr; 17(831):eadh1922. PubMed ID: 38593154
[TBL] [Abstract][Full Text] [Related]
26. PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
Beije N; Abida W; Antonarakis ES; Castro E; de Wit R; Fizazi K; Gillessen S; Hussain M; Mateo J; Morris MJ; Olmos D; Sartor O; Sharp A; Sweeney CJ; de Bono JS
Eur Urol; 2023 Sep; 84(3):253-256. PubMed ID: 37087376
[TBL] [Abstract][Full Text] [Related]
27.
Tien JC; Chang Y; Zhang Y; Chou J; Cheng Y; Wang X; Yang J; Mannan R; Shah P; Wang XM; Todd AJ; Eyunni S; Cheng C; Rebernick RJ; Xiao L; Bao Y; Neiswender J; Brough R; Pettitt SJ; Cao X; Miner SJ; Zhou L; Wu YM; Labanca E; Wang Y; Parolia A; Cieslik M; Robinson DR; Wang Z; Feng FY; Lord CJ; Ding K; Chinnaiyan AM
bioRxiv; 2024 Mar; ():. PubMed ID: 38562774
[TBL] [Abstract][Full Text] [Related]
28. Scaffold attachment factor B1 regulates androgen degradation pathways in prostate cancer.
Yang JS; Qian C; You S; Rotinen M; Posadas EM; Freedland SJ; Di Vizio D; Kim J; Freeman MR
Am J Clin Exp Urol; 2021; 9(4):337-349. PubMed ID: 34541032
[TBL] [Abstract][Full Text] [Related]
29. Novel quinazolin-4(3H)-one based Cyclin K degraders regulate alternative polyadenylation activity.
Sano O; Ito M; Saito M; Toita A; Tanaka T; Maezaki H; Araki S; Iwata H
Biochem Biophys Res Commun; 2023 Oct; 676():6-12. PubMed ID: 37480690
[TBL] [Abstract][Full Text] [Related]
30.
Wang X; Carvajal-Moreno J; Zhao X; Li J; Hernandez VA; Yalowich JC; Elton TS
Mol Pharmacol; 2024 May; ():. PubMed ID: 38719474
[TBL] [Abstract][Full Text] [Related]
31. CDK12-inactivation-induced MYC signaling causes dependency on the splicing kinase SRPK1.
Liang J; Gondane A; Itkonen HM
Mol Oncol; 2024 May; ():. PubMed ID: 38775167
[TBL] [Abstract][Full Text] [Related]
32. A potent new-scaffold androgen receptor antagonist discovered on the basis of a MIEC-SVM model.
Wang XY; Chai X; Shan LH; Xu XH; Xu L; Hou TJ; Sun HY; Li D
Acta Pharmacol Sin; 2024 May; ():. PubMed ID: 38750073
[TBL] [Abstract][Full Text] [Related]
33. InPACT: a computational method for accurate characterization of intronic polyadenylation from RNA sequencing data.
Liu X; Chen H; Li Z; Yang X; Jin W; Wang Y; Zheng J; Li L; Xuan C; Yuan J; Yang Y
Nat Commun; 2024 Mar; 15(1):2583. PubMed ID: 38519498
[TBL] [Abstract][Full Text] [Related]
34. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity.
Fan Z; Devlin JR; Hogg SJ; Doyle MA; Harrison PF; Todorovski I; Cluse LA; Knight DA; Sandow JJ; Gregory G; Fox A; Beilharz TH; Kwiatkowski N; Scott NE; Vidakovic AT; Kelly GP; Svejstrup JQ; Geyer M; Gray NS; Vervoort SJ; Johnstone RW
Sci Adv; 2020 May; 6(18):. PubMed ID: 32917631
[TBL] [Abstract][Full Text] [Related]
35. The landscape and clinical relevance of intronic polyadenylation in human cancers.
Cheng X; Jiang G; Zhou X; Wang J; Zhao Z; Zhang J; Ni T
J Genet Genomics; 2024 May; ():. PubMed ID: 38740258
[TBL] [Abstract][Full Text] [Related]
36. Combining enzalutamide with PARP inhibitors: Pharmaceutically induced BRCAness.
Thompson TC; Li L; Broom BM
Oncotarget; 2017 Nov; 8(55):93315-93316. PubMed ID: 29212150
[No Abstract] [Full Text] [Related]
37. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract][Full Text] [Related]
38. Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis.
Sun R; Yan B; Li H; Ding D; Wang L; Pang J; Ye D; Huang H
Cancer Res; 2023 Oct; 83(19):3192-3204. PubMed ID: 37527336
[TBL] [Abstract][Full Text] [Related]
39. Impact of DNA damage repair alterations on prostate cancer progression and metastasis.
Lukashchuk N; Barnicle A; Adelman CA; Armenia J; Kang J; Barrett JC; Harrington EA
Front Oncol; 2023; 13():1162644. PubMed ID: 37434977
[TBL] [Abstract][Full Text] [Related]
40. Use of PARP inhibitors in prostate cancer: from specific to broader application.
Zhang Z; Diao L; Zhang C; Wang F; Guan X; Yao X
Front Endocrinol (Lausanne); 2023; 14():1164067. PubMed ID: 37152924
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]